Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
Vertex Pharmaceuticals Incorporated VRTX announced updates on its two novel investigational candidates, zimislecel (formerly VX-880) and VX-264, which are being developed in separate studies for ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
Analysts' ratings for Vertex Pharmaceuticals (NASDAQ:VRTX) over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $502.55 ... At the same time, the Dow lost 0.37%, and the tech-heavy Nasdaq lost 0.53%. Heading into today, shares of ...
Vertex Pharmaceuticals (VRTX) closed the latest trading day at ... At the same time, the Dow lost 1.69%, and the tech-heavy Nasdaq lost 2.7%. The drugmaker's stock has climbed by 5.91% in the ...
Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback